Market
The Southern African pharmaceutical market continues to grow on demographic, epidemiological, and policy tailwinds. Generic and ethical medicines remain the largest and most accessible segment.
Investor relations
A growth story written in registered dossiers and regional reach.
LHC Pharmaceuticals is at an inflection point. With twenty years of operating history, an active eight-market distribution footprint, and a pipeline of more than twenty-five regulatory submissions, the next phase is about scale.
The opportunity
Position
Twenty years of regulatory experience, a registered portfolio, and a curated channel network are not commodities, they are accumulated infrastructure that takes a decade to build.
Network
Strategic partnership with KRKA, equity partnership with Black IQ Pharma, and channel partnerships with the most credible pharmacy networks in South Africa.
Pipeline
More than twenty-five active dossiers in SAHPRA review, including Linezolid LHC under Fast-Track. Each registration is a future revenue line.
Request the full Information Memorandum
The IM contains detailed financials, dossier-by-dossier pipeline information, and projection modelling. It is shared on request with qualified investors.